Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
06/21/2017 06/22/2017 06/23/2017 06/26/2017 06/27/2017 Date
56.07(c) 57.33(c) 56.64(c) 56.92(c) 56.195 Last
8 783 585 8 289 648 20 794 767 5 596 327 3 382 321 Volume
+0.74% +2.25% -1.20% +0.49% -1.27% Change
More quotes
Financials ($)
Sales 2017 20 264 M
EBIT 2017 5 470 M
Net income 2017 4 637 M
Debt 2017 74,3 M
Yield 2017 2,78%
Sales 2018 20 842 M
EBIT 2018 5 721 M
Net income 2018 5 067 M
Finance 2018 890 M
Yield 2018 2,88%
P/E ratio 2017 20,28
P/E ratio 2018 18,61
EV / Sales2017 4,63x
EV / Sales2018 4,46x
Capitalization 93 772 M
More Financials
Company
Bristol-Myers Squibb Co. operates as a biopharmaceutical company, which engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products.It includes chemically-synthesized drugs or small molecules and products produced from biological... 
Sector
Pharmaceuticals
Calendar
07/05Ex-dividend day
More about the company
Surperformance© ratings of Bristol-Myers Squibb Compa
Trading Rating : Investor Rating :
More Ratings
Latest news on BRISTOL-MYERS SQUIBB COMPA
06/24 BRISTOL MYERS SQUIBB : Four-Year Follow-up with Empliciti (elotuzumab) Plus Lena..
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/22 BRISTOL MYERS SQUIBB : Trademark Application for "ELZITUDE" Filed by Bristol-Mye..
06/22 BRISTOL MYERS SQUIBB : An Application for the Trademark "EMKELOS" Has Been Filed..
06/22 BRISTOL MYERS SQUIBB : to Announce Results for Second Quarter 2017 on July 27
06/22 BRISTOL MYERS SQUIBB : Extended Follow-Up Data Evaluating Opdivo nivolumab Shows..
06/22 BRISTOL MYERS SQUIBB : Supreme Court ruling could make it harder to file class-a..
06/21 BRISTOL MYERS SQUIBB : Announces the Expiration of its Cash Tender Offer
06/20 BRISTOL MYERS SQUIBB : Announces the Pricing Terms of its Cash Tender Offer For ..
06/20 BRISTOL MYERS SQUIBB : In WLF Victory, Supreme Court's Bristol-Myers Decision Li..
More news
Sector news : Pharmaceuticals - NEC
07:35pDJMERCK AND : Says Its Network Was Hit by Global Hack
06/26DJASTRAZENECA : ADRs End Mostly Higher
06/26 VALEANT PHARMACEUTICALS INTL : Hedge fund Paulson & Co discloses 6.3 percent sta..
06/26DJHow Third Point's Nestlé Move Could Affect L'Oréal
06/23DJSAMSUNG ELECTRONICS : Makes Play for Drug Market With Version of Humira -- Updat..
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on BRISTOL-MYERS SQUIBB COMPA 
2016Attractive price levels
More Strategies
Latest Tweets
08:07pMORE: S&P 500 health care index down about 0.5 percent; Johnson & Joh..
6
01:17pBristol-Myers Squibb Company's outperform rating reiterated at William Blair... 
11:00aNorthstar Asset Management LLC Cuts Stake in Bristol-Myers Squibb Company $BM.. 
10:54aBourgeon Capital Management LLC Acquires 2,900 Shares of Bristol-Myers Squibb.. 
03:47aDow Jones Analysis Video - $DJIA $DIA $SDOW $XOM $GE $GS $MRK $PFE $BMY $VZ .. 
More tweets
Qtime:137
News from SeekingAlpha
06/26 BIOTECH BOOM! : Overview And Company-By-Company Review
06/26 3 THINGS IN BIOTECH YOU SHOULD LEARN : June 26, 2017
06/24 Stocks to watch next week
06/22 BIOTECH FORUM DAILY DIGEST : Biotech Breaks Out! Spotlight On Aclaris Therapeuti..
06/22 Drug stocks rally on GOP draft of healthcare bill
Advertisement
Chart BRISTOL-MYERS SQUIBB COMPA
Duration : Period :
Bristol-Myers Squibb Compa Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQU...
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 57,1 $
Spread / Average Target 0,38%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Laurie H. Glimcher Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB C..-2.60%93 311
JOHNSON & JOHNSON18.42%367 520
NOVARTIS12.96%225 386
ROCHE HOLDING LTD.8.68%224 497
PFIZER4.80%203 487
MERCK AND COMPANY11.98%180 958
More Results